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Direct-acting antivirals for hepatitis C virus induce a rapid clinical and biochemical 
remission of porphyria cutanea tarda. 
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Dear Editor, 
  
Sporadic porphyria cutanea tarda (PCT) is strongly associated with HCV infection in our 
population 1,2,3,4. . Therapeutic options for PCT include phlebotomies and low-dose 4-
aminoquinolines, which show high rates of disease remission. However, some PCT patients 
may present frequent relapses attributable to resistance/intolerability/poor adherence to 
conventional treatments and/or persistence of risk factors. In 2014 we reported the first 
case of a patient with active PCT and HCV-HIV co-infection cured with direct antiviral agents 
(DAAs) 5. Herein, we present a larger cohort of patients, demonstrating the rapid and 
persistent remission of PCT with DAAs regimes administered for HVC infection.  
 
We treated 16 HVC-infected patients with active PCT from 2014 to 2016 with DAAs. PCT had 
been previously diagnosed in the Porphyria reference centre of Barcelona according to 
EPNET protocols and quality control schemes. In all patients, PCT remained clinically and 
biochemically active despite having been treated with phlebotomies and/or 4-
minoquinolines for years. All classic PCT treatments were stopped before the administration 
of DAAs regimes. Patients included are described in Table 1.  Examination of risk factors 
showed that 12 out of the 16 PCT- HCV patients treated with DAAs were co-infected with 
HIV. None of them had any other PCT- risk factor.  
 
Treatment was administered in all patients according to the EASL Recommendations6. We 
monitored the effect of the DAAs regimes on (a) HCV viral load (b) urine porphyrin levels.  
All treatments consisted of combinations of antiviral drugs that are known to have 
comparably high efficacy and safety. Fifteen of the 16 PCT-HCV patients were treated 
successfully for HCV with DAA regimens.  Exceptionally, one patient did not respond due to 
low treatment adherence.  
 
The registration of HCV viral load, porphyrins in plasma and urine before and after DAAs 
administration, showed that the eradication of HCV was followed by a decrease in urinary 
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The normalization of urinary porphyrin levels was followed by PCT clinical remission in all 
cases. This remission has been maintained over time, and no relapses of PCT have been 
detected during follow-up (mean: 1,18 years; range: 0-3 years).  
 
Our results show a striking, rapid and complete normalization of porphyrin urinary levels 
shortly after reaching undetectable RNA-HCV levels in blood tests. This suggests the very 
clear role of HCV in the maintenance of UROD inhibition rather than a mechanism in which 
the virus would only indirectly set off a chain of events ultimately leading to PCT. The rapid 
decline of plasma and urinary porphyrin levels indicates that once the HCV RNA replication 
is stopped in the hepatocyte, UROD restores its activity. 
 
However, while the eradication of the virus allows a rapid recovery of hepatic UROD activity, 
there is a long delay between HCV infection and the onset of PCT. The mechanisms involved 
in this delay and the susceptibility/genetic factors that may predispose a minority of HCV 
infected patients to develop PCT are still unknown. Further observations showed that PCT 
patients infected with HCV that reached clinical remission after phlebotomy and/or 
chloroquine (but presumably with the virus still active) presented a notable proportion of 
long-standing abnormal (PCT-type) urinary profiles7, suggesting a direct association between 
HCV replication within the hepatocytes and the formation of the putative UROD inhibitor.  
 
Until date, only other four cases of PCT-HCV patients successfully treated with DAAs regimes 
have been reported, however, their HIV/AIDS status was not specified8, 9.  
 
Therefore, our results might also help to elucidate the role that HIV infection plays in the 
development of PCT as most of our patients were co-infected with HIV. Among the co-
infected patients (HCV-HIV), the decline of the urinary porphyrin concentration occurred 
without any change in HIV status. This confirms our previous observations10, in which we 
reported that among 8000 patients infected with HIV that attended the Hospital Clinic de 
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The whole set of previous and new results indicate that; (a): the extraordinary effectiveness 
of new DAAs regimens in the elimination of HCV opens a plausible new approach to the 
treatment of PCT in which the disease, if associated with HCV infection, could be treated 
without employing the classic therapeutic options.  This clearly opens the path to expand 
this therapeutic approach as a single and unique therapeutic option in PCT patients with 
HCV-infection that may cure two diseases with one approach. (b): HIV might not play a 
direct role in PCT patients; (c): co-infection may reduce the therapeutic efficacy of classic 
PCT treatments, hence complicating remission; d) DAAs regimes efficacy to cure PCT is not 
attenuated by HCV/HIV co-infection in patients with undetectable HIV viral load.  
 
 
Follow-up is still short to completely discard PCT relapse, although the results obtained are 
encouraging and suggest maintenance of remission over time. For this reason, all patients 
have been recruited for a specific long-term follow-up program to assess their long-term 
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Table 1. Patients included, HIV status, programs of DAAs regimens administered to each 
patient, HCV viral load and porphyrin urinary levels. (Boc: Boceprevir, Dac: Daclastavir, Das: 
Dasabuvir, Ebv: Elbasvir, Gzp: Grazoprevir, IFN: Interferon, Ldp: Ledipasvir, Om:Ombitasvir, 
PegIFN: Pegylated Interferon, Pr: Paritaprevir, Rbv: Ribavirin, Rt: Ritonavir, Sim: Simeprevir, 
Sof: Sofosbuvir, Tlp: Telaprevir).  
 
Figure 1. Evolution of porphyrin urinary levels over time. A rapid and complete normalization of 
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